Nektar Therapeutics Stock
-
Your prediction
Nektar Therapeutics Stock
Nektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Pros and Cons of Nektar Therapeutics in the next few years
Pros
Cons
Performance of Nektar Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Nektar Therapeutics | - | - | - | - | - | - | - |
| Ironwood Pharmaceuticals | 0.000% | -4.132% | 3.571% | -67.778% | -72.381% | -88.984% | -84.324% |
| Novocure Ltd | -0.180% | -0.676% | 4.457% | -21.152% | -62.174% | -85.988% | -88.133% |
| Iovance Biotherapeutics Inc. | 3.390% | 6.827% | 0.200% | -77.850% | -72.404% | -80.894% | -93.071% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.In general, Nektar Therapeutics (NKTR) from the Biotechnology & Medical Research industry presents an interesting financial profile. The company seems to have struggled with net income over the last few years but maintains a consistent cash position and sizeable investments. Below is a comprehensive analysis of the company's financials, including notable pros and cons to consider.
Solid Cash Position: NKTR has maintained a reasonably strong cash position throughout the years, with an end-period cash balance of $102.6 million in 2020, $25.2 million in 2021, and $88.2 million in 2022. As of Q1 2023, the cash balance stands at $76.9 million, indicating that the company has been able to consistently generate and preserve cash.
Growing Total Assets: The company registered an increase in total assets from $1.54 billion in 2020 to $1.12 billion in 2021, although there was then a decrease to $710.6 million in 2022. Despite the recent decline, the overall trend in asset growth signifies that the business is expanding.
Comments
News
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?
Investors in the biotechnology space have been treated to a couple of big fireworks displays recently. During the month leading up to Sept. 19, shares of Nektar Therapeutics (NASDAQ: NKTR) and
Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today
Clinical-stage biotech Nektar Therapeutics (NASDAQ: NKTR) had some encouraging news to report from the lab about one of its investigational medicines on Thursday. As often happens in such
Why Nektar Therapeutics Rippled Higher This Week
Nektar Therapeutics (NASDAQ: NKTR) stock surged by more than 20% in the week to Friday morning. The move wasn't so much caused by anything specific to Nektar's drug development program. Instead